Operational Excellence in the Age of AI

Artificial intelligence isn't just changing what we do - it's quietly reshaping how we think and make decisions. In the pharma industry, we're moving from effortful cognition to a world where answers arrive fully formed: AI-driven quality decisions, predictive maintenance alerts, automated batch release recommendations. The friction that once deepened understanding - the analysis, the troubleshooting, the pattern recognition built through years of GMP experience - is disappearing. These systems are powerful, but they operate without experience or consequence. That creates a new tension: fluency without judgment.

Drawing on two decades of work at the intersection of technology, medicine, and human cognition, including advisory roles with Roche, the World Health Organization, and Google Health, alongside a scientific foundation in cardiovascular physiology, John Nosta explores this shift not as a warning, but as a design challenge.

As the pharma industry invests in digital transformation, continuous manufacturing, and AI-enabled quality systems, how do we engage these tools in ways that preserve the human discernment, operational accountability, and intellectual ownership that ensure compliance, safety, and competitive advantage? How do manufacturing professionals stay in control when machines start making recommendations that sound confident but lack real-world consequence?

This talk examines what happens to decision-making when AI removes the hard work of analysis, why that matters in regulated environments where judgment is non-negotiable, and how to use these systems in ways that keep human thinking active, intentional, and central to operational excellence.